EA202191339A1 - Новая форма изохинолинсульфонамида - Google Patents

Новая форма изохинолинсульфонамида

Info

Publication number
EA202191339A1
EA202191339A1 EA202191339A EA202191339A EA202191339A1 EA 202191339 A1 EA202191339 A1 EA 202191339A1 EA 202191339 A EA202191339 A EA 202191339A EA 202191339 A EA202191339 A EA 202191339A EA 202191339 A1 EA202191339 A1 EA 202191339A1
Authority
EA
Eurasian Patent Office
Prior art keywords
isoquinolinesulfonamide
new form
phenylpropylamino
isoquinoline
propan
Prior art date
Application number
EA202191339A
Other languages
English (en)
Inventor
Хироеси Хидака
Кенго Суми
Такаси Идзухара
Original Assignee
Д. Вестерн Терапьютикс Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Д. Вестерн Терапьютикс Инститьют, Инк. filed Critical Д. Вестерн Терапьютикс Инститьют, Инк.
Publication of EA202191339A1 publication Critical patent/EA202191339A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Представлен стабильный кристалл соли N-[(R)-1-{(S)-2-гидрокси-2-фенилпропиламино}пропан-2-ил]изохинолин-6-сульфонамида, обладающий свойствами, желательными для фармацевтической лекарственной субстанции, и, более конкретно, ангидрид дигидрохлорида N-[(R)-1-{(S)-2-гидрокси-2-фенилпропиламино}пропан-2-ил]изохинолин-6-сульфонамида.
EA202191339A 2018-12-17 2019-12-16 Новая форма изохинолинсульфонамида EA202191339A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018235213 2018-12-17
PCT/JP2019/049099 WO2020129876A1 (ja) 2018-12-17 2019-12-16 イソキノリンスルホンアミドの新規な形態

Publications (1)

Publication Number Publication Date
EA202191339A1 true EA202191339A1 (ru) 2021-08-27

Family

ID=71101331

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191339A EA202191339A1 (ru) 2018-12-17 2019-12-16 Новая форма изохинолинсульфонамида

Country Status (15)

Country Link
US (1) US11427546B2 (ru)
EP (1) EP3901141B1 (ru)
JP (1) JP7425482B2 (ru)
KR (1) KR20210104729A (ru)
CN (1) CN113195453B (ru)
AU (1) AU2019402422A1 (ru)
BR (1) BR112021011739A2 (ru)
CA (1) CA3120751A1 (ru)
DK (1) DK3901141T3 (ru)
EA (1) EA202191339A1 (ru)
FI (1) FI3901141T3 (ru)
MX (1) MX2021007233A (ru)
PT (1) PT3901141T (ru)
SG (1) SG11202105739YA (ru)
WO (1) WO2020129876A1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1370914A (en) 1971-07-06 1974-10-16 Ici Ltd Paint compositions
DE3943678C2 (de) * 1988-12-26 1999-11-25 Hiroyoshi Hidaka Isochinolinsulfonsäureamide, Verfahren zu deren Herstellung und diese Amide enthaltende pharmazeutische Zusammensetzung
US5340811A (en) 1990-03-08 1994-08-23 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinoline-or quinoline-sulfonamide derivative and a pharmaceutical composition comprising the same
DE69606721T2 (de) 1995-07-03 2000-06-21 Asahi Chemical Ind 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
JP2899953B2 (ja) 1995-07-03 1999-06-02 旭化成工業株式会社 １−（５−イソキノリンスルホニル）ホモピペラジン塩酸塩１／２水和物
MY139797A (en) 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
ES2396795T3 (es) 2007-07-02 2013-02-27 Asahi Kasei Pharma Corporation Compuesto de sulfonamida y cirstal del mismo
PT2657227T (pt) * 2010-12-22 2016-08-01 D Western Therapeutics Inst Inc Novo derivado de isoquinolina substituída
JP5819705B2 (ja) 2011-11-09 2015-11-24 興和株式会社 イソキノリン誘導体塩酸塩無水物結晶

Also Published As

Publication number Publication date
EP3901141A4 (en) 2022-07-13
FI3901141T3 (fi) 2024-03-01
WO2020129876A1 (ja) 2020-06-25
JP7425482B2 (ja) 2024-01-31
CA3120751A1 (en) 2020-06-25
MX2021007233A (es) 2021-07-15
EP3901141B1 (en) 2024-02-07
US11427546B2 (en) 2022-08-30
CN113195453B (zh) 2024-04-30
DK3901141T3 (da) 2024-02-26
JPWO2020129876A1 (ja) 2021-11-04
EP3901141A1 (en) 2021-10-27
KR20210104729A (ko) 2021-08-25
US20220017469A1 (en) 2022-01-20
BR112021011739A2 (pt) 2021-08-31
AU2019402422A8 (en) 2021-07-01
SG11202105739YA (en) 2021-07-29
PT3901141T (pt) 2024-03-04
AU2019402422A1 (en) 2021-06-17
CN113195453A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201990598A1 (ru) Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы
EA201790785A1 (ru) Производные тетрагидроизохинолина
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
MX2016014911A (es) Acidos hidroxamicos heterociclicos como inhibidores de proteina desacetilasa e inhibidores dobles de proteina desacetilasa-proteina cinasa, y metodos de uso de los mismos.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MX2021006969A (es) Ligante peptidico.
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
NZ767352A (en) Crystal form and salt form of pyridopyrazole compound and preparation method therefor
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
SA519402090B1 (ar) مثبطات انتقائية لـ hdac6، وطريقة تحضيرها، واستخدامها
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA201991373A1 (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)